Photo of Rona Yaeger from MSKCC/LinkedIn
Jun 27, 2024, 11:18
FDA approves the targeted therapy adagrasib for people with advanced colorectal cancer – MSKCC
Memorial Sloan Kettering Cancer Center shared a post on LinkedIn:
“The US Food and Drug Administration has approved the targeted therapy adagrasib in combination with another targeted therapy for people with advanced colorectal cancer caused by a gene mutation called KRAS-G12C. Dr. Rona Yaeger, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center (MSK), led the trial that resulted in this approval.
“Since we started this trial, I have had people coming to me from all over to receive this treatment,” Dr. Yaeger says. “Now that this drug combination is approved, many more patients will be able to benefit.”
Learn more here.”